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Abstract
Purpose Systemic chemotherapy still represents the gold stan-
dard in the treatment of irresectable colorectal liver metastases.
Modern anticancer agents like the monoclonal antibody cetux-
imab have improved the outcome of patients in clinical studies.
As hepatic arterial infusion (HAI) is capable to potentially
increase the anticancer effect of cytostatics, we herein studied
whether HAI of cetuximab (CE) as a single agent or in combi-
nation with oxaliplatin (OX) exerts increased anticancer effects
compared to the systemic application (SYS) of the drugs.
Methods WAG/Rij rats were randomized to eight groups and
underwent 10 days after subcapsular hepatic tumor implanta-
tion either HAI or SYS of CE, OX, or the combination of both
agents (CE + OX). Saline-treated animals served as controls.
Tumor volume was measured at days 10 and 13 using three-
dimensional ultrasound. On day 13, liver and tumor tissue was
sampled for histological and immunohistochemical analysis.
Results In controls, the tumor volume significantly increased
from day 10 to 13. Application of OX alone via HAI or SYS did
not inhibit tumor growth compared to controls. SYS of CE or
CE + OX did also not reduce tumor growth. In contrast, HAI of
CE and CE + OX significantly inhibited tumor growth. HAI of
CE significantly reduced tumor vascularization as measured by
the number of platelet endothelial cell adhesion molecule-1-
positive cells and significantly increased the number of apopto-
tic tumor cells as measured by the cellular caspase-3 expression.
Conclusion HAI of CE and CE + OX reduces tumor growth
of colorectal rat liver metastases involving the inhibition of
angiogenesis and induction of tumor cell apoptosis.
Keywords Colorectal liver metastases . Locoregional
chemotherapy . Hepatic arterial infusion . Systemic
chemotherapy . Monoclonal antibody
Introduction
Colorectal cancer is one of the most common malignancies
in the western world and has rising incidence in Asia either
[1]. About 50 % of colorectal cancer patients develop liver
metastases with a statistical 5-year survival of 10–20 % [2].
Today, due to novel and multimodal therapies, treatment
options for hepatic colorectal metastases are manifold. How-
ever, the patient population is very inhomogeneous. In
patients with irresectable liver metastases, the 5-year surviv-
al rate is almost zero. In contrast, patients with resectable
metastases can even be healed by surgical treatment.
Systemic chemotherapy plays a key role in colorectal
cancer patients, regardless of whether the therapeutic inten-
tion is curative or palliative. The response rate of the classic
intravenous 5-fluorouracil/folinic acid chemotherapy regime
is about 20 %. In the past years, it has been shown that by
adding oxaliplatin or irinotecan (FOLFOX and FOLFIRI
regimens) the response rate is doubled [3]. Cetuximab, a
chimeric monoclonal IgG1 antibody directed against the
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ligand-binding domain of the epidermal growth factor re-
ceptor (EGF-R), belongs to a group of novel anti-cancer
agents. Its additional application has led to a further improve-
ment of the outcome of metastatic colorectal cancer treatment,
albeit restricted to patients with wild-type K-ras status [4–6].
However, even with modern systemic chemotherapy regi-
mens, the 2-year survival rate still does not exceed 40 % [7].
Despite an ongoing discussion about the oncological
benefit of hepatic arterial infusion (HAI), it is known that
HAI is capable of augmenting the antineoplastic effects of
anticancer agents, and therefore, it is recommended from
some centers [8–11]. A recent Cochrane review of Mocellin
et al. concluded that the future of HAI seems to be linked to
the delivery of novel cancer agents or drug combinations
[12]. Accordingly, we herein studied in a rat liver metastasis
model, whether HAI compared to SYS of cetuximab with or
without the combination of oxaliplatin is capable of increas-
ing the antitumor effect of these agents.
Materials and methods
Binding of cetuximab
To analyze the specific binding of cetuximab to the surface of
the cells of the rat colon carcinoma cell line CC531, in vitro
immunocytochemical fluorescence staining was performed.
After fixing with 4 % phosphate-buffered formalin and block-
ing of unspecific binding sites with 1 % donkey serum,
CC531 cells were incubated with the primary antibody con-
centrate cetuximab for 2 h at 37 °C. A Cy-3-labeled donkey
antihuman IgG antibody was incubated for 30 min at the
concentration of 1:50 (Jackson by Dianova GmbH, Hamburg,
Germany) and was used as secondary antibody. Cell nuclei
were stained with 2 μg/mL bisbenzimide (Sigma, Tauf-
kirchen, Germany). The cells were visualized by fluorescence
microscopy (Fig. 1). In four separate experiments, the number
of positively stained cells was counted in 20 high-power fields
(each experiment) and is given in percent of all cells analyzed.
In vitro cell viability analysis
To assess the effect of cetuximab on the viability of cultured
CC531 cells, a water-soluble tetrazolium (WST)-1 assay was
performed according to the manufacturer’s instructions (Roche,
Mannheim, Germany). For this purpose, 1×104 cells per well
were seeded in 100 μL RPMI medium with 20 % fetal calf
serum,100 U/mL penicillin, and 0.1 mg/mL streptomycin
(PAA, Cölbe, Germany) on a 9-well plate. After overnight
culturing at 37 °C in a humidified atmosphere containing 5 %
CO2, cells were treated with cetuximab in concentrations of 1,
10, 100, 1,000, 2,500, or 5,000 μg/mL for 24 h.WST-1 reagent
(10 μL) was added, and the absorption was measured after
30 min at 450 nm and at 620 nm as reference, using a micro-
plate reader. The measured data were corrected to the blank
values without cells.
Drugs
Cetuximab was given in a dose of 125 mg/m2, and oxaliplatin,
in a dose of 85 mg/m2. To calculate the body surface area, we
used “Meeh’s formula,” assuming that it is proportional to the
two-thirds power of the body weight. The formula reads as
follows: A0K×W2/3, where A represents the body surface
area; K, an animal specific constant; and W, the body weight.
In the present study, a K value of 9.1 was used [13].
Rat liver metastasis model
All experiments were approved by the local governmental ethic
committee. Forty-eight male WAG/Rij rats with a mean body
weight of 267.5±5.9 g were used to perform the experiments.
Animals were randomized in eight groups (n06 each) and kept
in a temperature- and humidity-controlled 12-h light/dark cycle
environment with free access to water and standard laboratory
chow (Altromin, Lage, Germany). For the induction of colo-
rectal liver metastases, a median laparotomy was performed
under ether anesthesia. Using a 27 G needle (Omnicon F,
Braun, Melsungen, Germany) 5×105 cells of the syngeneic
CC531 colon carcinoma cell line were injected under the cap-
sule of the lower surface of the left liver lobe. Laparotomy was
closed by a one-layer running PDS 4–0 suture (Ethicon/John-
son & Johnson MEDICAL GmbH, Norderstedt, Germany).
Surgical procedure
Ten days after tumor cell implantation, animals were
relaparotomized under ether anesthesia. For the HAI
Fig. 1 Immunocytochemical fluorescence microscopy of CC531 cells
in vitro. a The staining of the nuclei of the cells (cells are stained blue).
b The binding of cetuximab (stained red) on the CC531 cells; c the
merge of a and b. d The negative control
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procedure, the gastroduodenal artery was cannulated (ID
0.28 mm, Portex, Hythe, UK). The tip of the catheter
was positioned at the common hepatic artery. During the
HAI procedure, the hepatic artery was not occluded and
showed orthograde blood flow. After the HAI procedure, the
catheter was removed, and the gastroduodenal artery was
ligated. For the SYS procedure, the subhepatic vena cava
was punctured with a 23-G needle (Troge Medical GmbH,
Hamburg, Germany) according to previously published
standards [14].
Experimental protocol
Animals were randomized to eight groups (n06 each) in-
cluding four subgroups of animals undergoing HAI and four
subgroups undergoing SYS. After tumor cell implantation
(day 0), relaparotomy was performed on day 10, and ani-
mals received either cetuximab (CE), oxaliplatin (OX), or
the combination of both (CE + OX) via HAI or SYS. Sham
controls received an equivalent amount of 0.9 % saline
solution (Braun, Melsungen, Germany). HAI or SYS pro-
cedure was performed for a time period of 1 min followed
by ultrasound imaging. Three days later (day 13), animals
underwent relaparotomy for final ultrasound imaging. Ani-
mals were sacrificed, and tissue samples were asserved for
histological and immunohistochemical analysis. The body
weight of the animals was measured on days 0, 10, and 13 to
determine weight reduction due to the treatment.
Three-dimensional ultrasound imaging
For evaluation of the tumor volume, the 40-MHz ultrasound
probe of the Vevo 770 high-resolution imaging system
(VisualSonics, Inc., Toronto, Ontario, Canada) was used.
Ultrasound imaging was performed on the liver surface on
days 10 and 13. For three-dimensional imaging, parallel
two-dimensional images were acquired in 50-μm intervals
controlled by a stepping motor. The three-dimensional re-
construction was achieved by off-line outlining the tumor
dimension every 200 μm on the two-dimensional images.
Using these data, the integrated software of the ultrasound
device produced a polygonal three-dimensional image and
calculated the tumor volume.
Sampling and assays
Via puncture of the subhepatic vena cava, venous blood
samples were taken at day 10 before drug administration
and at day 13 before ultrasound imaging. As indicators of
hepatocellular injury, aspartate aminotransferase (ASAT),
alanine aminotransferase (ALAT) and glutamate dehydroge-
nase (GLDH) serum activities were determined using rou-
tine spectrophotometry.
Histology
Tissue specimens of the tumor and the surrounding liver
parenchyma were fixed in 4 % phosphate-buffered formalin
and embedded in paraffin. Histological analysis of hepato-
cellular injury, venular endothelial detachment and venular
fibrin clotting, was performed using sections of 5 μm
stained with hematoxylin–eosin. Hepatocellular injury was
determined by analysis of hepatocellular vacuolization with
a semiquantitative score: 00none; 10mild; 20moderate;
and 30severe. Venular endothelial detachment was assessed
by counting the number of venules with detachment of
endothelial lining cells and is given in percent of all venules
analyzed. Accordingly, the number of venules with fibrin
clots was counted, and fibrin clotting is given in percent of
all venules analyzed.
Immunohistochemistry
For immunohistochemistry tissue slides were deparaffi-
nized, and proteins were unmasked with citrate buffer at a
pH of 6. The endogenous peroxidases were blocked with
3 % H2O2 in methanol, and unspecific proteins were
blocked with 3 % goat serum.
Cleaved caspase-3 (cysteine-aspartic proteases) as an
indicator of apoptotic cell death was used. Five-
micrometer sections of paraffin-embedded tumor-
bearing liver specimens were incubated overnight at
room temperature with a rabbit polyclonal anti-cleaved
caspase-3 antibody (1:50, Cell Signaling Technology, Frank-
furt, Germany). As secondary antibody, a peroxidase-
conjugated goat anti-rabbit IgG antibody (1:100, Dianova,
Hamburg, Germany) was used. 3.3′-Diaminobenzidine was
used as chromogen. The sections were counterstained with
hemalaun. Positively stained cells were counted in 25 high-
power fields (HPF) per specimen and are given as number per
HPF.
Proliferating cell nuclear antigen (PCNA) served as an
indicator of cell proliferation. Five-micrometer sections of
paraffin-embedded specimens were incubated for 18 h at
4 °C with a mouse monoclonal anti-PCNA antibody (1:50;
Dako, Hamburg, Germany). For development of PCNA, a
peroxidase-conjugated goat anti-mouse IgG antibody
(1:100; Dianova) was incubated for 30 min. 3.3′-Diamino-
benzidine was used as chromogen, and hemalaun was used
for counterstaining. Sections were analyzed using a score
ranging from 0 to 4 of PCNA-positive cells (0≤1 %, 101–
10 %, 2010–30 %, 3030–50 %, 4≥50 % of PCNA-positive
cells).
Platelet endothelial cell adhesion molecule-1 (PECAM-1;
CD31) served as an indicator for vascularization. For
immunohistochemical detection of PECAM-1 expres-
sion, a primary mouse anti-rat antibody (1:500; clone
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TLD-3 A12, Serotec) was used, and a peroxidase-
conjugated goat anti-mouse antibody (Dianova) was
used as secondary antibody. PECAM-1-positive blood
vessels were given as number per HPF (counted in 25
HPF per section).
Statistical analysis
All values are expressed as mean ± SEM. After analysis of
the normal distribution of data and homogeneity of variance,
differences between the groups were calculated by one-way
analysis of variance followed by the Student–Newman–
Keuls test. The pairwise comparison was performed by
Student’s t test. Overall statistical significance was set at
p<0.05. Statistical analysis was performed with the use
of SigmaStat (SPSS, Inc., Chicago, USA).
Results
Binding of cetuximab
Specific in vitro binding experiments using immunocy-
tochemical fluorescence staining showed that cetuximab
binds to the surface of CC531 cells (Fig. 1). Quantita-
tive analysis revealed 92.5±0.4 % positively stained
cells, indicating a high affinity of cetuximab to the
CC531 cells.
In vitro cell viability after cetuximab exposure
After 30-min exposure of CC531 cells to 2,500 and
5,000 μg/ml cetuximab, the WST assay showed a significant
reduction of cell viability to ~12 and ~3 % [optical density
(OD) 0.034±0.003 and 0.009±0.002] compared to controls
(OD 0.283±0.011). Similar results were observed after
1-h exposure (OD 0.086±0.001 and 0.012±0.001 vs 0.446±
0.002). Cetuximab concentrations of <1,000 μg/ml did not
significantly affect CC531 cell viability.
Metastatic tumor growth and general health conditions
After 10 days of tumor growth, all animals established a
solitary tumor in the left liver lobe with a diameter of about
5 to 10 mm. Signs of extrahepatic disease were not ob-
served. Animals were not affected systemically by the ma-
lignant process. Analysis of the body weight could not
detect a significant difference of weight change from days
0 to 13 between HAI- and SYS-treated animals (Table 1). Of
interest, SYS of CE, CE + OX, and OX showed significant-
ly less weight gain compared to SYS Sham. In contrast, after
HAI only, OX alone showed a reduced weight gain com-
pared to sham (Table 1).
Metastatic tumor growth
From days 10 to 13, tumor size increased by more than 50 %
in HAI controls (HAI Sham) and more than 40 % in SYS
controls (SYS Sham) without significant difference when
comparing the two groups (Fig. 2). Oxaliplatin given as
monotherapy via HAI (HAI OX) showed a slight but not
significant inhibition of tumor growth compared to HAI




CE + OX −2.0±1.3 −4.5±1.2*
OX −6.9±1.9* −4.3±1.6*
Weight change from days 0 to 13 in percent of the body weight at day
0. Animals were treated either with hepatic arterial infusion or systemic
application of saline (Sham), cetuximab, the combination of cetuximab
and oxaliplatin, or oxaliplatin alone. There were no statistically signifi-
cant differences comparing HAI to SYS. Mean ± SEM
HAI hepatic arterial infusion, SYS systemic application, CE cetuximab,
CE + OX combination of cetuximab and oxaliplatin, OX oxaliplatin
*p<0.05 vs Sham of the corresponding group



































Fig. 2 a, b The tumor volume at day 13 in percent of the volume
measured at day 10 after HAI (a) and SYS (b) of cetuximab (CE),
oxaliplatin (OX), or the combination of both (CE + OX). Animals
undergoing HAI or SYS with saline served as controls (Sham). Data
are given as mean ± SEM; *p<0.05 vs Sham; #p<0.05 vs
corresponding SYS
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sham (Fig. 2), whereas SYS OX did not show any effect
(Fig. 2). Of interest, HAI of cetuximab alone (HAI CE) or in
combination with oxaliplatin (HAI CE + OX) significantly
inhibited tumor growth compared to HAI sham and the
corresponding SYS groups (Fig. 2).
Tumor cell proliferation
In all groups, tumors showed a high proliferation rate as
measured by PCNA-positive immunohistochemistry. There
was no substantial difference in tumor cell proliferation
between HAI- and SYS-treated animals (Fig. 3). The pro-
liferation rate within the surrounding liver tissue was signif-
icantly lower compared to the tumor tissue. However, there
were also no differences between the groups (Fig. 3).
Apoptotic tumor cell death
Apoptotic cell death in the unaffected liver tissue was over-
all neglectable. Analysis of the number of apoptotic cells in
the tumors revealed that sham controls and monotherapy
with oxaliplatin did not show any relevant differences
between HAI and SYS. Of interest, systemic application of
the drugs did not show significant differences compared to
SYS Sham (Fig. 4). In contrast, CE and CE + OX via HAI
induced a significant three- to fourfold increase of apoptotic
cell death compared to both HAI Sham as well as SYS CE
and SYS CE + OX (Fig. 4).
Tumor vascularization
In sham controls, the number of tumor vessels, indicated by
PECAM-1-positive cells, was 11.9±0.9 in HAI-treated
tumors and 10.5±1.7 per HPF in SYS-treated tumors. SYS
OX reduced the number of blood vessels per HPF by about
40 %. HAI OX was even more effective and reduced the
number of blood vessels by about 70 % compared to sham
control. SYS or HAI of CE and, in particular, HAI CE + OX
were also highly effective in reducing the number of tumor
blood vessels (Fig. 5).
Hepatocellular injury
Analysis of the liver enzymes ASAT and ALAT as indicators
















































Fig. 3 a, b The data of the immunohistochemical analysis of proliferating
nuclear cell antigen (score 00<1%, 101–10%, 2010–30%, 3030–50%,
and 4≥50 % of PCNA-positive cells) of liver and tumor tissue of animals
undergoing HAI (a) or SYS (b) with cetuximab (CE), oxaliplatin (OX),
or the combination of both (CE + OX). Animals undergoing HAI or SYS
with saline served as controls (Sham). Data are given as mean ± SEM;



























































Fig. 4 a, b The quantitative analysis of cleaved caspase-3-positive
cells of liver and tumor tissue (given as number per HPF) of animals
undergoing HAI (a) or SYS (b) with cetuximab (CE), oxaliplatin (OX),
or the combination of both (CE + OX). Animals undergoing HAI or SYS
with saline served as controls (Sham). Data are given as mean ± SEM;
*p<0.05 vs Sham; #p<0.05 vs corresponding SYS
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significant differences between the HAI and SYS groups
(data not shown). Analysis of the GLDH activity from days
10 and 13 showed a slight increase after HAI CE + OX and
HAI OX (Table 2).
Histomorphological analysis of hepatocellular vacuoliza-
tion, endothelial detachment, or vascular fibrin clotting did
not reveal relevant differences between HAI and SYS after
Sham, OX, CE, and CE + OX treatment (data not shown).
Discussion
The major finding of the present study is that cetuximab via
HAI but not via SYS as monotherapy or in combination
with oxaliplatin is effective to inhibit tumor growth of
colorectal liver metastases in the rat. Colorectal cancer is
the second leading cause of cancer death worldwide. About
20 % of the patients show synchronous hepatic metastases,
and up to 30 % develop metachronous disease [15]. There-
fore, the control of this hepatic disease remains a challeng-
ing issue. Systemic chemotherapy is a substantial part of the
treatment of colorectal liver metastases. Moreover, hepatic
arterial infusion is used in some centers with different results
[8–11]. In a recent Cochrane review, Mocellin et al. con-
cluded that the future of HAI seems to be linked to the use
of novel anticancer agents or drug combinations [12]. Bou-
chahda et al. also claimed that the role of HAI should be
revisited using modern therapeutic approaches [16]. Thus,
HAI is moving again in the focus of scientific interest in
clinical and experimental studies and plays an increasing
role in the treatment of liver-limited metastatic colorectal
cancer [7, 14, 17–19]. HAI, as locoregional chemotherapy,
bears the advantage to increase the local concentration of
tumoricidal agents within liver metastases. The rationale for
HAI is that hepatic metastases receive their nutritive blood
supply mostly from the hepatic arterial system, while the
hepatic tissue is fed predominantly by the portal venous
blood flow [20]. Moreover, whereas the portal vein via the
Glisson Trias directly drains into the liver sinusoids, part of
the arterial blood at first drains into the peribiliary plexus
before entering the sinusoidal system [21]. Tumor vessels of
hepatic metastases are supplied by this arterial blood flow
[22], which leads to a prolonged exposure time of drugs
applied via the arterial system. This probably caused the
increased antitumor effect seen after HAI compared to SYS
in the present study [23]. Moreover, hepatic arterial drug
application can lead to high extraction rates of drugs via the
first-pass effect and consecutively less side effects [7].
Therefore, agents with high extraction rates are particularly
attractive for HAI. While in former clinical trials, HAI was
predominantly performed with floxuridine or 5-FU, newer
trials included oxaliplatin with encouraging results [8, 9, 14,
24, 25].
Oxaliplatin, plays a key role in chemotherapy of colorec-
tal cancer because of a large spectrum of anticancer activity
together with mild toxicity [26–28]. However, in the present
study, a measureable reduction of tumor growth was only























































Fig. 5 a, b The number of PECAM-1-positive blood vessels per HPF
in tumors of animals undergoing HAI (a) or SYS (b) with cetuximab
(CE), oxaliplatin (OX), or the combination of both (CE + OX). Ani-
mals undergoing HAI or SYS with saline served as controls (Sham).
Data are given as mean ± SEM; *p<0.05 vs Sham; #p<0.05 vs
corresponding SYS
Table 2 Liver enzyme GLDH (in units per liter) at days 10 and 13
Group Day 10 Day 13
HAI SYS HAI SYS
Sham 22.3±7.1 34.3±10.3 35.0±5.8 22.3±6.5
CE 49.9±9.7 23.2±6.6 44.6±8.4 22.9±9.8
CE + OX 24.7±6.4 38.6±14.2 72.2±5.1 20.8±6.9*
OX 30.5±6.2 35.2±5.9 59.8±34.8 15.1±2.9
Animals were treated either with hepatic arterial infusion or systemic
application of saline (Sham), cetuximab, or oxaliplatin alone or the
combination of cetuximab and oxaliplatin. HAI of cetuximab and oxali-
platin led to a significant increase of GLDH from days 10 to 13 compared
to the systemic administration form (SYS CE + OX). Mean ± SEM
HAI hepatic arterial infusion, SYS systemic application, CE cetuximab,
OX oxaliplatin, CE + OX combination of cetuximab and oxaliplatin,
HAI CE + OX HAI of cetuximab and oxaliplatin
*p<0.05 vs HAI
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seen in animals treated by HAI of cetuximab alone or in
combination with oxaliplatin. HAI or SYS of oxaliplatin
alone did not inhibit tumor growth in the present liver
metastasis model. This is not surprising because, from clin-
ical findings, it is known that oxaliplatin monotherapy
exerts only minimal antineoplastic effects [29]. According-
ly, in clinical studies, oxaliplatin is not given as a single
drug, but only in combination with other antineoplastic
agents [29]. The present study was conducted as a “proof
of principle” study, where a single application of the drugs
in a short time period was chosen to evaluate whether HAI
of the drug in the fast growing CC531 metastases is superior
to inhibit tumor growth compared to SYS.
Cetuximab, a novel anticancer agent, is a monoclonal human/
murine chimeric anti-epidermal growth factor receptor antibody,
who is selectively active in the subpopulation of wild-type K-ras.
EGF-R is overexpressed in colorectal cancer and correlates with
a poorer prognosis and higher resistance to systemic chemother-
apy [30–32]. Deregulation of EGF-R is linked to inhibition of
tumor proliferation, invasion, migration, angiogenesis, and resis-
tance to apoptosis [33]. The tumor cell line CC531, which was
used in the present study, also expresses the EGF-R on its
surface. As shown by the present study, cetuximab binds to
EGF-R on the surface of the CC531 tumor cells.
In a preclinical trial, Van Buren et al. demonstrated that,
after partial hemihepatectomy, a monoclonal EGF-R antibody
had no effect on liver regeneration [34]. This view is in line
with the results observed in the present study, where neither
HAI nor SYS of cetuximab induced relevant side effects.
In clinical trials, intravenous cetuximab shows its efficacy
in the treatment of colorectal liver metastases both as a single
agent in second-line treatments as well as in combination with
irinotecan- or oxaliplatin-based therapy regimens in first-line
treatments [4, 5, 35–38]. Accordingly, today, intravenous ap-
plication of cetuximab is clinical standard in the treatment of
colorectal liver metastases, albeit restricted to wild-type K-ras
cases. However, Azzopardi and coworkers claim that these
results are still inconclusive. Even in patients with wild-type
K-ras an interindividual variability in response to cetuximab is
observed [39]. In the present study, systemic application of
cetuximab did not inhibit tumor growth. This is most probably
due to the fact that the CC531 tumor cell line used exhibits a
mutated K-ras gene in codon 12 (GGT to GAT), changing
glycine to aspartic acid [40]. This is in line with the results of
clinical studies, also demonstrating no significant effect of
cetuximab on progression-free survival and overall survival
in K-ras-mutated tumors [41]. Therefore, the results of our
study are of particular interest because a comparable dose of
cetuximab, when given via HAI, was not only capable of
inhibiting the growth but also of decreasing the volume of
the K-ras-mutated CC531 tumor. These in vivo results are
supported by our in vitro analyses, demonstrating that, in high
concentrations, cetuximab is capable of significantly reducing
CC531 cell viability. Because the application of the mAb by
HAI provides an increased concentration, this might explain
the unexpected observation of an increased antitumor effect in
the present study.
In conclusion, the present study shows that HAI of cetux-
imab alone or in combination with oxaliplatin is effective to
inhibit tumor growth of colorectal liver metastases in the rat,
whereas SYS was ineffective. Thus, HAI chemotherapy with
cetuximab and oxaliplatin may represent a promising ap-
proach in the treatment of colorectal liver metastases.
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